About
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company founded in 2011 and based in Garden City, New York, with operations in Israel. The company focuses on developing innovative therapies and diagnostic tools that utilize nitric oxide (NO) to enhance treatment outcomes for respiratory diseases, neurological disorders, and certain cancers. The core product platform, LungFit, includes several systems: LungFit PH, which is approved for treating persistent pulmonary hypertension of the newborn; LungFit PRO, currently in development for viral lung infections; and LungFit GO, designed for at-home treatment of nontuberculous mycobacteria infections. Beyond Air is also advancing ultra-high concentration nitric oxide therapies and selective neuronal nitric oxide synthase inhibitors for neurological conditions. The company operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos, providing clinical support and training for healthcare providers. Led by CEO Steve Lisi, Beyond Air aims to improve lives through its innovative approaches, addressing unmet medical needs in respiratory care and beyond.
Technologies
Keywords
Company Information
-
Employees 110
-
Founded 2011
-
Annual Revenue $3705000
-
Total Funding $78170000
Location
301 Stewart Ave, Garden City, New York, United States, 11530-2745
